EUVIMEDEUVIMED entdecken
BeobachtungsstudieOpen Access · CC BY 4.0

Immunogenicity of SARS-CoV-2 mRNA Vaccine in Breast Cancer Patients Undergoing Active Treatment: A Prospective Observational Study

María Leonor Fernández-Murga iD, Lucía Serrano-García iD, Giuseppe D'Auria iD, María Portero Hernández, Llúcia Martínez-Priego iD, Loreto Ferrús-Abad, Griselda de Marco, María Victoria Domínguez-Márquez, Antonio Llombart-Cussac iD

Pathogens · 2025

DOI: 10.3390/pathogens14090947 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift Pathogens, 2025. Verfasst von María Leonor Fernández-Murga und 8 weiteren Autor:innen. Beteiligte Einrichtung: Molecular Oncology Laboratory, Arnau de Vilanova Hospital, Foundation for the Promotion of Health and Biomedical Research of the Valencian Community …. Hauptthemen laut MEDLINE: Breast Neoplasms, COVID-19, SARS-CoV-2, COVID-19 Vaccines. Die Arbeit nennt 53 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Consellería de Sanitat Universal i Salut Pública (Generalitat Valenciana, Spain and the EU Operational Program of the European Regional Development Fund (ERDF)…, Consellería de Sanitat Universal i Salut Pública (Generalitat Valenciana, Spain), EU Operational Program of the European Regional Development Fund (ERDF) for the Valencian Community 2014–2020.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Understanding the immune response to SARS-CoV-2 vaccination in cancer patients remains a critical priority given their immunocompromised status. In this prospective observational study, we evaluated humoral and cellular immunity across three time points—baseline, post-second dose, and post-booster—in 23 breast cancer patients undergoing active treatment. IgG antibody levels showed a significant increase following vaccination, with a 300-fold rise after the second dose and a 2200-fold increase post-booster, indicating a strong humoral response. CD19+ B cells also increased significantly, supporting B cell-mediated activation. Although overall T cell frequencies remained stable, we observed a shift toward memory phenotypes, with decreased naïve CD4+ and CD8+ T cells and increased central and peripheral memory subsets after the booster. Notably, CD8+ TEMRA cells expanded significantly, suggesting cytotoxic memory formation. Correlation analyses linked peripheral memory CD4+ T cells with anti-SARS-CoV-2 IgG titers, while CD8+ TEMRA cells showed an inverse association. Antigen-specific CD8+ T cell response was evaluated using APC-labeled MHC I Dextramer reagents. After the booster, 55.5% of patients developed detectable antigen-specific CD8+ T cells, whereas 44.5% did not. Importantly, one patient who failed to develop antigen-specific CD8+ T cells experienced a mild SARS-CoV-2 infection, suggesting that the absence of this response may increase susceptibility despite high IgG levels. These findings indicate that antigen-specific CD8+ T cell responses and antibody levels may act as complementary but not directly correlated arms of immunity. Microbiota profiling via sPLS-DA suggested weak but distinct microbial signatures associated with immune responsiveness, particularly enrichment of taxa such as Alistipes and Romoutsia among high-antibody responders. These findings emphasize that SARS-CoV-2 vaccination is immunogenic and well tolerated in breast cancer patients under therapy and highlight the need to further explore microbiota–immune interactions to optimize vaccination strategies in oncology.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Breast NeoplasmsCOVID-19SARS-CoV-2COVID-19 VaccinesImmunogenicity, VaccineHumansFemaleProspective StudiesMiddle AgedAntibodies, ViralImmunoglobulin GAdultCD8-Positive T-LymphocytesAgedImmunity, CellularImmunity, HumoralCD4-Positive T-Lymphocytes

Stichwörter der Autor:innen

SARS-CoV-2antibodiesbreast cancermRNA vaccinemicrobiome

Substanzen

COVID-19 VaccinesAntibodies, ViralImmunoglobulin G

Autor:innen und Institutionen

  • Molecular Oncology Laboratory, Arnau de Vilanova Hospital, Foundation for the Promotion of Health and Biomedical Research of the Valencian Community (FISABIO), 46015 Valencia, Spain.
  • Sequencing and Bioinformatics Service, Foundation for the Promotion of Health and Biomedical Research of the Valencian Community (FISABIO), Avda. de Catalunya 21, 46020 Valencia, Spain.
  • Microbiology Department, Arnau de Vilanova Hospital, Foundation for the Promotion of Health and Biomedical Research of the Valencian Community (FISABIO), 46015 Valencia, Spain.

ORCID-Profile: María Leonor Fernández-Murga, Lucía Serrano-García, Giuseppe D'Auria, Llúcia Martínez-Priego, Antonio Llombart-Cussac

Förderung

  • Consellería de Sanitat Universal i Salut Pública (Generalitat Valenciana, Spain and the EU Operational Program of the European Regional Development Fund (ERDF)…
  • Consellería de Sanitat Universal i Salut Pública (Generalitat Valenciana, Spain)
  • EU Operational Program of the European Regional Development Fund (ERDF) for the Valencian Community 2014–2020

Zitieren

APA

Fernández-Murga, M. L., Serrano-García, L., D'Auria, G., Hernández, M. P., Martínez-Priego, L., Ferrús-Abad, L., de Marco, G., Domínguez-Márquez, M. V., & Llombart-Cussac, A. (2025). Immunogenicity of SARS-CoV-2 mRNA Vaccine in Breast Cancer Patients Undergoing Active Treatment: A Prospective Observational Study. Pathogens. https://doi.org/10.3390/pathogens14090947

Vancouver

Fernández-Murga ML, Serrano-García L, D'Auria G, Hernández MP, Martínez-Priego L, Ferrús-Abad L, et al. Immunogenicity of SARS-CoV-2 mRNA Vaccine in Breast Cancer Patients Undergoing Active Treatment: A Prospective Observational Study. Pathogens. 2025. doi:10.3390/pathogens14090947

BibTeX
@article{FernndezMurga2025,
  author = {Fernández-Murga, María Leonor and Serrano-García, Lucía and D'Auria, Giuseppe and Hernández, María Portero and Martínez-Priego, Llúcia and Ferrús-Abad, Loreto and de Marco, Griselda and Domínguez-Márquez, María Victoria and Llombart-Cussac, Antonio},
  title = {Immunogenicity of SARS-CoV-2 mRNA Vaccine in Breast Cancer Patients Undergoing Active Treatment: A Prospective Observational Study},
  journal = {Pathogens},
  year = {2025},
  doi = {10.3390/pathogens14090947}
}
Kostenlos starten →